Not confined to so-called autoimmune diseases, MHC fine-mapping studies have successfully identified the risk HLA variants of different diseases, such as infectious diseases [75, 76], malignant tumors [77, 78], and neurological diseases [7, 79]. This evidence concerns the gene HLA-C and cancer.